CRMD

CorMedix Inc.

Fundamental data last updated:August 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

 


Analyze CRMD on TradingView

VALUATION

P/E

3.70

Market Cap ($M USD)

$660.56M

Forward P/E

6.28

PEG

-0.15

PRICE TO SALES

1.65

PRICE TO BOOK

1.53

EV / EBITDA

2.84

5-Year Average P/E

Free Cash Flow Yield

29.73%

DCF Value

$2.48

Graham Number

$16.78

Price to FCF

3.36

EV to FCF

3.19

Earnings Yield

27.04%

FCF Yield

29.73%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$2.28

Next Year EPS Growth Estimate

$1.34

Next Year Revenue Growth Estimate

$512.86M

Return on Equity (ROE)

50.38%

FREE CASH FLOW

Operating Margin

48.41%

Debt-to-Equity

0.37

Piotroski F-Score

4

Altman Z-Score

2.41

Return on Invested Capital (ROIC)

28.20%

Current Ratio

2.98

Quick Ratio

2.74

Net Debt to EBITDA

-0.15

Interest Coverage

69.87

Gross Profit margin

85.83%

FCF PER SHARE

$2.47

REVENUE PER SHARE

$5.03

Analyze CRMD on TradingView

Gainseekers Quantitative Analysis

Summary

CRMD CorMedix Inc. presents a perplexing valuation scenario. Despite a robust Earnings Yield of 26.11% and a Forward P/E of 4, the stock has been trading significantly below its DCF Value and Graham Number. This suggests a potential market mispricing, possibly due to its Altman Z-score of 1.82, which indicates financial distress risk. The company’s impressive Return on Equity of 58.50% and Operating Margin of 48.17% highlight strong operational efficiency, yet the market seems cautious, perhaps due to the biotech sector’s inherent volatility.

AI Exposure / Tech Reliance

As a biotechnology firm, CorMedix is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's rapid tech evolution aligns with their innovative focus, potentially enhancing R&D efficiency. However, the challenge remains in integrating these technologies swiftly to maintain a competitive edge.

The Bull Case

For value or GARP investors, CorMedix offers compelling reasons to buy. With a stellar ROIC of 23.03% and a Free Cash Flow Yield of 28.08%, the company demonstrates exceptional capital efficiency and cash generation. The Piotroski F-Score of 5, coupled with a Gross Profit Margin of 88.46%, underscores its pricing power and operational prowess. These metrics paint a picture of a company capable of delivering strong returns on invested capital.

The Bear Case

Despite its strengths, CorMedix faces significant structural risks. The stock's Price/Book ratio of 1.54 and Price/Sales ratio of 1.99 suggest it may not be as undervalued as it appears. Additionally, the stock's recent pricing indicated it was extended above its 50-Day SMA, hinting at potential overvaluation. The low Altman Z-score further raises concerns about financial stability, making it a risky bet for cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$14.00

Institutional Ownership %

1-Year Beta

1.46

Insider Buying % (6 Mo)

Distance to 52-Week High

107.01%

Distance to 52-Week Low

27.20%

EARNINGS SURPRISE %

22.86%

50-DAY SMA

$7.39

200-DAY SMA

$9.53

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.